Maria Kislikova, Almudena Vega, Eduardo Verde, Soraya Abad, Marco Vaca, Adriana Acosta, Angela González, Arturo Bascuñana, Antonia Mijailova, Coraima Nava, Miguel Villa, Juan Carlos Ruiz, Marian Goicoechea
{"title":"透析器东丽 NV-U® Hydrolink™ 对介质分子的去污能力：用于进行在线血液渗滤的新型亲水膜。","authors":"Maria Kislikova, Almudena Vega, Eduardo Verde, Soraya Abad, Marco Vaca, Adriana Acosta, Angela González, Arturo Bascuñana, Antonia Mijailova, Coraima Nava, Miguel Villa, Juan Carlos Ruiz, Marian Goicoechea","doi":"10.1177/03913988241274735","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>New dialysis membranes with new properties are being developed to improve efficacy and tolerance. The hemocompatibility of a polymeric biomaterial is influenced by the layer of water at the blood membrane interface. The new dialyzer TORAY NV-U<sup>®</sup> has a membrane Hydrolink™, designed to suppress platelet adhesion and to improve the hemocompatibility. Until now, there is no experience in online hemodiafiltration (OL-HDF).The objective of the present study is to evaluate the efficacy of this new membrane in OL-HDF therapy compared to another membrane commonly used. Other objectives are to evaluate the inflammatory response, hemodynamic tolerance, and the anticoagulation regimes.</p><p><strong>Methods: </strong>This is a prospective pilot study performed in five anuric patients receiving OL-HDF. For 1 month patients were kept with their usual dialyzer FX1000<sup>®</sup> (FMC). Subsequently, the dialyzer was changed to TORAY NV-U<sup>®</sup> (Hydrolink<sup>®</sup>) for 1 month. In the last dialysis session of each dialyzer, blood tests were performed to evaluate inflammation and depurative capacity.</p><p><strong>Results: </strong>We did not find differences in medium size removal molecules and convective volume: FX1000<sup>®</sup>: 31 ± 9 l per session and Hydrolink™ 30 ± 8 l; <i>p</i> = 0.7); β2microglobulin reduction ratio (RR) FX1000<sup>®</sup> FMC 83 ± 3%; Hydrolink™ 79 ± 4; <i>p</i> = 0.14; Myoglobin RR FX1000<sup>®</sup> FMC 72 ± 7%; Hydrolink™ 76 ± 4; <i>p</i> = 0.28. We did not find differences in inflammation parameters: serum IL6 with FX1000<sup>®</sup> 6.0 ± 4.2 pg/mL; Hydrolink™ 7.6 ± 5.0 pg/mL; <i>p</i> = 0.3.During all sessions with the two dialyzers there was adequate plasmatic filling, reaching 85 % filling. All patients had \"good\" dialyzer status in all dialysis sessions with TORAY NV-U<sup>®</sup>, while the dialyzer status with FX1000<sup>®</sup> was \"good\" in 20% of the sessions, \"medium\" in 30%, and \"dirty\" in the remaining 50% dialysis sessions.</p><p><strong>Conclusions: </strong>The new dialyzer Hydrolink™, TORAY NV-U<sup>®</sup> is not inferior to perform OL-HDF compared to dialyzers usually used for this therapy, and could allow decrease heparin doses. Further studies with a bigger sample size and longer follow-up will answer if Hydrolink improves inflammation and assess a better hemodynamic tolerance.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Depurative capacity toward medium molecules of the dialyzer Toray NV-U<sup>®</sup> Hydrolink™: A new hydrophilic membrane to perform online hemodiafiltration.\",\"authors\":\"Maria Kislikova, Almudena Vega, Eduardo Verde, Soraya Abad, Marco Vaca, Adriana Acosta, Angela González, Arturo Bascuñana, Antonia Mijailova, Coraima Nava, Miguel Villa, Juan Carlos Ruiz, Marian Goicoechea\",\"doi\":\"10.1177/03913988241274735\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>New dialysis membranes with new properties are being developed to improve efficacy and tolerance. The hemocompatibility of a polymeric biomaterial is influenced by the layer of water at the blood membrane interface. The new dialyzer TORAY NV-U<sup>®</sup> has a membrane Hydrolink™, designed to suppress platelet adhesion and to improve the hemocompatibility. Until now, there is no experience in online hemodiafiltration (OL-HDF).The objective of the present study is to evaluate the efficacy of this new membrane in OL-HDF therapy compared to another membrane commonly used. Other objectives are to evaluate the inflammatory response, hemodynamic tolerance, and the anticoagulation regimes.</p><p><strong>Methods: </strong>This is a prospective pilot study performed in five anuric patients receiving OL-HDF. For 1 month patients were kept with their usual dialyzer FX1000<sup>®</sup> (FMC). Subsequently, the dialyzer was changed to TORAY NV-U<sup>®</sup> (Hydrolink<sup>®</sup>) for 1 month. In the last dialysis session of each dialyzer, blood tests were performed to evaluate inflammation and depurative capacity.</p><p><strong>Results: </strong>We did not find differences in medium size removal molecules and convective volume: FX1000<sup>®</sup>: 31 ± 9 l per session and Hydrolink™ 30 ± 8 l; <i>p</i> = 0.7); β2microglobulin reduction ratio (RR) FX1000<sup>®</sup> FMC 83 ± 3%; Hydrolink™ 79 ± 4; <i>p</i> = 0.14; Myoglobin RR FX1000<sup>®</sup> FMC 72 ± 7%; Hydrolink™ 76 ± 4; <i>p</i> = 0.28. We did not find differences in inflammation parameters: serum IL6 with FX1000<sup>®</sup> 6.0 ± 4.2 pg/mL; Hydrolink™ 7.6 ± 5.0 pg/mL; <i>p</i> = 0.3.During all sessions with the two dialyzers there was adequate plasmatic filling, reaching 85 % filling. All patients had \\\"good\\\" dialyzer status in all dialysis sessions with TORAY NV-U<sup>®</sup>, while the dialyzer status with FX1000<sup>®</sup> was \\\"good\\\" in 20% of the sessions, \\\"medium\\\" in 30%, and \\\"dirty\\\" in the remaining 50% dialysis sessions.</p><p><strong>Conclusions: </strong>The new dialyzer Hydrolink™, TORAY NV-U<sup>®</sup> is not inferior to perform OL-HDF compared to dialyzers usually used for this therapy, and could allow decrease heparin doses. Further studies with a bigger sample size and longer follow-up will answer if Hydrolink improves inflammation and assess a better hemodynamic tolerance.</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1177/03913988241274735\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/03913988241274735","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Depurative capacity toward medium molecules of the dialyzer Toray NV-U® Hydrolink™: A new hydrophilic membrane to perform online hemodiafiltration.
Introduction: New dialysis membranes with new properties are being developed to improve efficacy and tolerance. The hemocompatibility of a polymeric biomaterial is influenced by the layer of water at the blood membrane interface. The new dialyzer TORAY NV-U® has a membrane Hydrolink™, designed to suppress platelet adhesion and to improve the hemocompatibility. Until now, there is no experience in online hemodiafiltration (OL-HDF).The objective of the present study is to evaluate the efficacy of this new membrane in OL-HDF therapy compared to another membrane commonly used. Other objectives are to evaluate the inflammatory response, hemodynamic tolerance, and the anticoagulation regimes.
Methods: This is a prospective pilot study performed in five anuric patients receiving OL-HDF. For 1 month patients were kept with their usual dialyzer FX1000® (FMC). Subsequently, the dialyzer was changed to TORAY NV-U® (Hydrolink®) for 1 month. In the last dialysis session of each dialyzer, blood tests were performed to evaluate inflammation and depurative capacity.
Results: We did not find differences in medium size removal molecules and convective volume: FX1000®: 31 ± 9 l per session and Hydrolink™ 30 ± 8 l; p = 0.7); β2microglobulin reduction ratio (RR) FX1000® FMC 83 ± 3%; Hydrolink™ 79 ± 4; p = 0.14; Myoglobin RR FX1000® FMC 72 ± 7%; Hydrolink™ 76 ± 4; p = 0.28. We did not find differences in inflammation parameters: serum IL6 with FX1000® 6.0 ± 4.2 pg/mL; Hydrolink™ 7.6 ± 5.0 pg/mL; p = 0.3.During all sessions with the two dialyzers there was adequate plasmatic filling, reaching 85 % filling. All patients had "good" dialyzer status in all dialysis sessions with TORAY NV-U®, while the dialyzer status with FX1000® was "good" in 20% of the sessions, "medium" in 30%, and "dirty" in the remaining 50% dialysis sessions.
Conclusions: The new dialyzer Hydrolink™, TORAY NV-U® is not inferior to perform OL-HDF compared to dialyzers usually used for this therapy, and could allow decrease heparin doses. Further studies with a bigger sample size and longer follow-up will answer if Hydrolink improves inflammation and assess a better hemodynamic tolerance.
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
